Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
Vertex Pharmaceuticals(VRTX) stock is priced at $462.62, giving the company a market capitalization of 117.52B. It carries a P/E multiple of 30.42.
During the trading session on 2026-03-17, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $468.45 and a low of $461.59. At a current price of $462.62, the stock is +0.2% higher than the low and still -1.2% under the high.
Trading volume for Vertex Pharmaceuticals(VRTX) stock has reached 648.32K, versus its average volume of 1.51M.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $517.20 and a low of $362.50.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $517.20 and a low of $362.50.
VRTX News
Key Points The biotech company is the leader in the cystic fibrosis market and is quickly expanding into other treatment areas. Vertex forecasts its newer med...
Key Points One of Vertex Pharmaceuticals' leading pipeline candidates just aced a phase 3 study. It could become an important growth driver while helping the...
If you are wondering whether Vertex Pharmaceuticals at around US$492 per share is still a good deal or already pricing in a lot of optimism, you are asking the...
Analyst ratings
74%
of 35 ratingsMore VRTX News
Truist analyst Joon Lee raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $525 from $490 and keeps a Buy rating on the shares. The company repo...
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive late-stage trial results for kidney disease drug povetacicept in IgA nephropathy. The drug met both pr...
Wolfe Research analyst Andy Chen upgraded Vera Therapeutics (VERA) to Outperform from Peer Perform with an $88 price target. Vertex’s (VRTX) reported interim da...
Vertex Pharmaceuticals VRTX announced positive data from an interim analysis of the ongoing phase III RAINER study, which evaluated its investigational drug pov...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.